Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting, 4743 [2014-01632]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 19 / Wednesday, January 29, 2014 / Notices
Potential Commercial Applications:
• Diagnostic biomarker of DHF
• Point-of-care diagnostic testing
• Enzyme-linked immunosorbent
assay (ELISA) for clinical and laboratory
use
Competitive Advantages:
• While there are commerciallyavailable ELISAs to detect vitronectin,
these products have not been used for
dengue diagnosis
• Vitronectin assessment assays
provide a novel, specific biomarker for
the DHF disease state
• Easily developed for serologic
diagnostic assays
Development Stage:
• Pre-clinical
• In vitro data available
Inventors: Elizabeth Hunsperger
(CDC), Momar Ndao (McGill
University), Kay Tomashek (CDC), Betty
Poole-Smith (CDC)
Publication: Poole-Smith BK, et al.
Discovery and Validation of Prognostic
Biomarkers for Severe Dengue by
Proteomic Screening. International
Conference on Emerging Infectious
Diseases 2012: poster and oral
presentation abstracts. Emerg Infect Dis.
2012 Mar. [https://wwwnc.cdc.gov/eid/
pdfs/ICEID2012.pdf ]
Intellectual Property: HHS Reference
No. E–147–2013/0—
• PCT Application No. PCT/US2012/
025472 filed 16 Feb 2012, which
published as WO 2013/130029 on 06
Sep 2013
• US Patent Application No. 13/
985,507 filed 14 Aug 2013
Licensing Contact: Whitney Blair, J.D.,
M.P.H.; 301–435–4937; whitney.blair@
nih.gov.
tkelley on DSK3SPTVN1PROD with NOTICES
Real-Time RT–PCR Assay for Detection
of Noroviruses
Description of Technology: A specific
and sensitive TaqMan-based real-time
(rt) RT–PCR assay has been developed
by CDC scientists for detection of
noroviruses in clinical and
environmental specimens. This assay
can be implemented to rapidly detect
and distinguish norovirus strains from
genogroups I and II, which are
responsible for the majority of human
infections. Additionally, the assay is
multiplexed with an internal extraction
control virus (coliphage MS2) to
validate the results of the assay. Since
the virus cannot be grown in cell culture
and enzyme immunoassays lack the
necessary sensitivity, this technology is
particularly useful.
Potential Commercial Applications:
• Development of norovirus
diagnostics
• Specific rtRT–PCR assay for
detecting and distinguishing of the
VerDate Mar<15>2010
16:05 Jan 28, 2014
Jkt 232001
major pathogenic norovirus genogroups
(I and II) within clinical and
environmental samples
Competitive Advantages:
• This is an internally controlled,
multiplexed assay capable of rapid,
accurate identification of norovirus
genogroups responsible for human
illness
• Superior sensitivity compared with
immunoassay detection methods
Development Stage:
• Pre-clinical
• In vitro data available
Inventors: Jan Vinje, Nicole
Gregoricus, Preeti Chhabra, Leslie
Barclay, Hannah Shirley, David Lee (all
of CDC)
Publications:
1. Vega E, et al. Novel surveillance
network for norovirus gastroenteritis
outbreaks, United States. Emerg Infect
Dis. 2011 Aug;17(8):1389–95. [PMID
21801614]
2. Schultz AC, et al. Development and
evaluation of novel one-step TaqMan
realtime RT–PCR assays for the
detection and direct genotyping of
genogroup I and II noroviruses. J Clin
Virol. 2011 Mar;50(3):230–4. [PMID
21195660]
Intellectual Property: HHS Reference
No. E–145–2013/0—PCT Application
No. PCT/US2012/065269 filed 15 Nov
2012, which published as WO 2013/
074785 on 23 May 2013
Licensing Contact: Whitney Blair, J.D.,
M.P.H.; 301–435–4937; whitney.blair@
nih.gov.
Dated: January 23, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–01635 Filed 1–28–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The concept review and
the discussions could disclose
confidential trade secrets or commercial
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
4743
property such as patentable material,
and personal information concerning
individuals associated with the concept
review, the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Fetal Body
Composition and Volumes in the NICHD
Fetal Growth Studies.
Date: February 12, 2014.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate concept
review.
Place: National Institutes of Health, 6100
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Sathasiva B. Kandasamy,
Ph.D., Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6100
Executive Boulevard, Rockville, MD 20892–
9304, (301) 435–6680, skandasa@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS).
Dated: January 23, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–01632 Filed 1–28–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development;
Special Emphasis Panel.
Date: February 3, 2014.
E:\FR\FM\29JAN1.SGM
29JAN1
]]>Agencies
[Federal Register Volume 79, Number 19 (Wednesday, January 29, 2014)]
[Notices]
[Page 4743]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-01632]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National Institute of Child Health & Human
Development; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The concept review and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the concept review, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Child Health and Human
Development Special Emphasis Panel; Fetal Body Composition and
Volumes in the NICHD Fetal Growth Studies.
Date: February 12, 2014.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate concept review.
Place: National Institutes of Health, 6100 Executive Boulevard,
Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Sathasiva B. Kandasamy, Ph.D., Scientific Review
Officer, Division of Scientific Review, National Institute of Child
Health and Human Development, 6100 Executive Boulevard, Rockville,
MD 20892-9304, (301) 435-6680, skandasa@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.864,
Population Research; 93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation Research; 93.209,
Contraception and Infertility Loan Repayment Program, National
Institutes of Health, HHS).
Dated: January 23, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-01632 Filed 1-28-14; 8:45 am]
BILLING CODE 4140-01-P
